A 4-year-old boy from Delhi presents with intense itching and erythematous, lichenified plaques over the flexural surfaces of his elbows and knees for the past 18 months. His mother reports the rash worsens during winter and improves in summer. On examination, he has dry skin (xerosis), Dennie–Morgan folds, and an elevated serum IgE level of 850 IU/mL. He has a personal history of allergic rhinitis and a family history of asthma in his father. What is the most appropriate first-line topical agent for managing the acute flare in this patient?

Explanation

## Diagnosis and Management of Atopic Dermatitis ### Clinical Features Confirming Atopic Dermatitis This patient meets the **Hanifin and Rajka criteria** for atopic dermatitis: - Pruritus (intense itching) - Flexural distribution (elbows, knees) - Chronic/relapsing course (18 months) - Early age of onset (4 years) - Personal history of atopy (allergic rhinitis) - Family history of atopy (father with asthma) - Xerosis and Dennie–Morgan folds (periorbital skin folds) - Elevated serum IgE **Key Point:** Atopic dermatitis is a chronic, relapsing inflammatory skin disorder characterized by intense pruritus, xerosis, and a predisposition to cutaneous infections due to impaired skin barrier function. ### First-Line Topical Treatment Hierarchy | Severity | First-Line Agent | Indication | |----------|------------------|------------| | Mild (limited area, minimal symptoms) | Emollients + mild topical steroid (hydrocortisone 1%) | Maintenance and mild flares | | Moderate (widespread or significant symptoms) | **Potent topical corticosteroid** (mometasone, fluticasone) | Acute flares with inflammation | | Severe or steroid-sparing | Topical calcineurin inhibitor (tacrolimus, pimecrolimus) | Face, neck, intertriginous areas; steroid-dependent cases | **High-Yield:** Topical corticosteroids remain the gold standard first-line agent for acute flares of atopic dermatitis because they rapidly reduce inflammation and pruritus. Potency is selected based on body site and severity. ### Why Mometasone Furoate 0.1% Is Correct - **Potent corticosteroid** (Class III–IV) suitable for moderate-to-severe flares - **Rapid anti-inflammatory effect** reduces erythema and lichenification - **Appropriate for body surface** (trunk and extremities; avoid face) - **Evidence-based:** Guideline-recommended first-line for acute AD flares - **Safe in children** when used for short durations (typically 2–4 weeks) **Clinical Pearl:** The combination of topical corticosteroid + emollients is superior to either alone. Emollients should be applied immediately after bathing to trap moisture in the stratum corneum. ### Management Algorithm ```mermaid flowchart TD A[Atopic Dermatitis Flare]:::outcome --> B{Severity & Location?}:::decision B -->|Mild, localized| C[Hydrocortisone 1% + emollients]:::action B -->|Moderate, widespread| D[Potent topical steroid<br/>e.g., mometasone 0.1%]:::action B -->|Face/neck/intertriginous| E[Calcineurin inhibitor<br/>tacrolimus 0.03%]:::action B -->|Severe/refractory| F[Systemic therapy<br/>cyclosporine, dupilumab]:::action D --> G[Apply BID for 2-4 weeks]:::action G --> H[Reassess & taper]:::action H --> I[Maintenance with emollients<br/>+ mild steroid PRN]:::outcome ``` **Mnemonic:** **ACES** for atopic dermatitis management: - **A**void triggers (irritants, allergens, stress) - **C**orticosteroids (topical, first-line) - **E**mollients (frequent, liberal use) - **S**kin care (gentle cleansing, moisturizing) ### Why Emollients Alone Are Insufficient While emollients are essential for maintenance and mild disease, this patient has **acute inflammation** (erythema, lichenification) requiring anti-inflammatory therapy. Emollients alone would delay symptom relief and risk disease progression.